You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Exelixis Returns vs. S&P
|1 Year||5 Year||5 Year Annualized||Since IPO|
Exelixis Company Info
A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.
News & Analysis
Here are the five best biotech ETFs to invest in right now.
Don't be too quick to dismiss this company as a one-trick pony.
These stocks are still bargain-priced but benefit from long-term trends.
Despite a challenging year for the markets, this growth stock managed to stand out with another stellar quarter.
These stocks have low-to-no debt, and analysts see tons of upside.
Cheap stocks have the ability to generate enormous, long-term profits for investors.
These two drug makers have outshined the market this year.
These drugmakers are flying high right now.
EXEL earnings call for the period ending September 30, 2022.
EXEL earnings call for the period ending June 30, 2022.
EXEL earnings call for the period ending March 31, 2022.
EXEL earnings call for the period ending December 31, 2021.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.